World AMR Awareness Week 2026 runs from 18 to 24 November under the theme “One Health, one action: Prevent AMR now”. This week, the JAFRAL team is going blue for AMR. Our contribution is to make phage therapy available when frontline antibiotics fail, as a treatment that works alongside them.
In a Global Cause campaign with The Guardian, our CEO Dr Frenk Smrekar explains why phage therapy, a century-old idea, is regaining ground as a precise, targeted treatment.

Phages work where antibiotics can’t
Bacteriophages are natural viruses that infect and kill bacteria. Each phage targets a specific bacterial strain and leaves everything else untouched, including the patient’s microbiome.
Matched to the patient in days
Advances in sequencing and biologics production mean a phage can now be matched to an infection in days, not months. JAFRAL screens the patient’s bacterial isolate against ready-made phages. If one is active, the phage can be delivered within two to three days. If not, a new phage can be produced from scratch within two to three weeks.
JAFRAL was the first company worldwide to list its GMP products in the EudraGMDP database as an inspected active substance. It has manufactured clinical trial products for 14 clinical trials.
From personalised to routine care
No phage product has full marketing authorisation in the EU or US yet, so patients are treated with individually prepared phages. “Regulators have been cooperative and proactive in recent years,” says Dr Smrekar. “The manufacturing side is ready; we have GMP capacity and phage banks in place. What’s needed now is more clinical trials and real-world evidence, and we’re contributing to them.”
“Once the technology is well tested, it makes sense to use phages earlier, alongside antibiotics, and relieve the burden on antibiotic use.” – Dr Frenk Smrekar
Read the full article: Phage therapy could be the answer when frontline treatments fail - Global Cause